"Halucinogeny p\u0159edstavuj\u00ED skupinu psychotropn\u011B p\u016Fsob\u00EDc\u00EDch l\u00E1tek, kter\u00E9 navozuj\u00ED charakteristick\u00E9 kognitivn\u00ED, percep\u010Dn\u00ED a emo\u010Dn\u00ED p\u0159\u00EDznaky. Mezi halucinogeny \u0159ad\u00EDme jednoduch\u00E9 halucinogenn\u011B p\u016Fsob\u00EDc\u00ED indolaminy (nap\u0159. psilocybin a DMT), ergolinov\u00E9 deriv\u00E1ty s indolov\u00FDm j\u00E1drem (LSD) a n\u011Bkter\u00E9 substituovan\u00E9 fenyletylaminy (meskalin). \u00DA\u010Dinek halucinogen\u016F je ve sv\u00E9 fenomenologii podobn\u00FD \u00FA\u010Dinku antagonist\u016F NMDA glutamatergn\u00EDch receptor\u016F (ketamin, fencyklidin nebo MK-801). Efekt halucinogen\u016F je spojen\u00FD s agonizmem serotoninov\u00FDch 5-HT2A, 5-HT1A a 5-HT2C receptor\u016F, se zm\u011Bnou funkce glutamatergn\u00EDch neuron\u016F a je potencov\u00E1n p\u0159\u00EDm\u00FDm nebo nep\u0159\u00EDm\u00FDm dopaminergn\u00EDm p\u016Fsoben\u00EDm a stimulac\u00ED noradrenergn\u00ED. Mechanizmus \u00FA\u010Dinku halucinogen\u016F a NMDA antagonist\u016F se pak prol\u00EDn\u00E1 na \u00FArovni glutamatergn\u00EDho i monoaminergn\u00EDho p\u016Fsoben\u00ED. Studium mechanizmu p\u016Fsoben\u00ED halucinogen\u016F poskytuje n\u00E1stroj studia patofyziologie du\u0161evn\u00EDch poruch (p\u0159edev\u0161\u00EDm schizofrenie) a \u00FA\u010Dinku antipsychotik."@cs . "2"^^ . . . "12" . . "Suppl. 3" . "2"^^ . "Neurobiology of the effects of hallucinogens and dissociative anesthetics"@en . . "Neurobiologie \u00FA\u010Dinku halucinogen\u016F a disociativn\u00EDch anestetik"@cs . . "CZ - \u010Cesk\u00E1 republika" . . "RIV/00023752:_____/08:00000848" . "[F716D4A310EB]" . . "P(1M0517), P(NR8785), P(NR8792)" . . . . . . "RIV/00023752:_____/08:00000848!RIV09-MZ0-00023752" . . . . "Hallucinogens represent the group of psychotropics, which induce characteristic cognitive, perceptual and emotional symptoms. Hallucinogens are represented by indolamines (psilocybin or DMT), ergoline derivatives with indole nucleus (LSD), and substituted phenylethylamines (mescaline). The clinical effect of hallucinogens is similar to the antagonists of NMDA glutamatergic receptors (ketamine, phencyclidine and MK-801). The effect of hallucinogens is mediated by the agonism on serotonin 5-HT2A, 5-HT1A a 5-HT2C receptors with subsequent change of activity of pyramidal glutamatergic neurons and by direct or indirect changes in dopaminergic and noradrenergic activity. The mechanisms of action of hallucinogens and NMDA antagonists overlap in changes induced in glutamatergic and monoaminergic systems. Studies of overlapping mechanisms of action of hallucinogens and NMDA antagonists represent important tool for the research in the field of pathophysiology of mental disorders (schizophrenia) and antipsychot"@en . . . "Neurobiologie \u00FA\u010Dinku halucinogen\u016F a disociativn\u00EDch anestetik" . "hallucinogens; NMDA; dissociative anesthetics; antipsychotics; serotonin; LSD; psilocybin; mescaline; glutamate; ketamine; phencyclidine; 5-HT2A receptor; noradrenalin; dopamin"@en . "Neurobiologie \u00FA\u010Dinku halucinogen\u016F a disociativn\u00EDch anestetik" . . "P\u00E1len\u00ED\u010Dek, Tom\u00E1\u0161" . "Neurobiologie \u00FA\u010Dinku halucinogen\u016F a disociativn\u00EDch anestetik"@cs . "Psychiatrie" . . "Hor\u00E1\u010Dek, Ji\u0159\u00ED" . "13"^^ . . . "Halucinogeny p\u0159edstavuj\u00ED skupinu psychotropn\u011B p\u016Fsob\u00EDc\u00EDch l\u00E1tek, kter\u00E9 navozuj\u00ED charakteristick\u00E9 kognitivn\u00ED, percep\u010Dn\u00ED a emo\u010Dn\u00ED p\u0159\u00EDznaky. Mezi halucinogeny \u0159ad\u00EDme jednoduch\u00E9 halucinogenn\u011B p\u016Fsob\u00EDc\u00ED indolaminy (nap\u0159. psilocybin a DMT), ergolinov\u00E9 deriv\u00E1ty s indolov\u00FDm j\u00E1drem (LSD) a n\u011Bkter\u00E9 substituovan\u00E9 fenyletylaminy (meskalin). \u00DA\u010Dinek halucinogen\u016F je ve sv\u00E9 fenomenologii podobn\u00FD \u00FA\u010Dinku antagonist\u016F NMDA glutamatergn\u00EDch receptor\u016F (ketamin, fencyklidin nebo MK-801). Efekt halucinogen\u016F je spojen\u00FD s agonizmem serotoninov\u00FDch 5-HT2A, 5-HT1A a 5-HT2C receptor\u016F, se zm\u011Bnou funkce glutamatergn\u00EDch neuron\u016F a je potencov\u00E1n p\u0159\u00EDm\u00FDm nebo nep\u0159\u00EDm\u00FDm dopaminergn\u00EDm p\u016Fsoben\u00EDm a stimulac\u00ED noradrenergn\u00ED. Mechanizmus \u00FA\u010Dinku halucinogen\u016F a NMDA antagonist\u016F se pak prol\u00EDn\u00E1 na \u00FArovni glutamatergn\u00EDho i monoaminergn\u00EDho p\u016Fsoben\u00ED. Studium mechanizmu p\u016Fsoben\u00ED halucinogen\u016F poskytuje n\u00E1stroj studia patofyziologie du\u0161evn\u00EDch poruch (p\u0159edev\u0161\u00EDm schizofrenie) a \u00FA\u010Dinku antipsychotik." . . . . "382407" . . . "Neurobiology of the effects of hallucinogens and dissociative anesthetics"@en . . . "1211-7579" . .